ProvexisCHIX:PXSL Days Payable is 115.58 as of Sep. 2025, which is 37% below its 10-year median of 182.50. The stock has 1 warning sign investors should review. Among 920 Drug Manufacturers companies, Provexis ranks better than 84.24% on this metric.
Provexis's average Accounts Payable for the
six
months ended in Sep. 2025 was £0.12 Mil. Provexis's Cost of Goods Sold for the
six
months ended in Sep. 2025 was £0.20 Mil.
Hence, Provexis's Days Payable for the
six
months ended in Sep. 2025 was 115.58.
The historical rank and industry rank for Provexis's Days Payable or its related term are showing as below:
CHIX:PXSl'
s Days Payable Range Over the Past 10 Years
Min: 11.78 Med: 182.5 Max: 1788.5
Current: 197.64
During the past 13 years, Provexis's highest Days Payable was 1788.50. The lowest was 11.78. And the median was 182.50.
CHIX:PXSl's Days Payable is ranked better than 84.24% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs CHIX:PXSl: 197.64
Provexis's Days Payable
increased
from Sep. 2024 (87.69) to Sep. 2025 (115.58).
It may suggest that Provexisdelayed paying its suppliers.
Provexis Days Payable Related Terms
Provexis Days Payable Historical Data
* Premium members only.
The historical data trend for Provexis's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:PXSL vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Provexis's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Provexis Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Provexis's Days Payable distribution charts can be found below:
* The bar in red indicates where Provexis's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Provexis's Days Payable for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Provexis (CHIX:PXSL) has a Days Payable of 115.58 as of Sep. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Provexis and its competitors. This is 37% below median its historical median of 182.50. Over the past decade, Provexis' Days Payable has ranged from 11.78 to 1,788.50. According to the industry distribution chart, Provexis ranks #145 out of 920 companies in the Drug Manufacturers industry, placing it in the top 15.8%.
Is Provexis' Days Payable too high?
Provexis' current Days Payable of 115.58 is 37% below median its 10-year median of 182.50. Over the past 10 years, this metric has ranged from a low of 11.78 to a high of 1,788.50. The Drug Manufacturers industry median Days Payable is 90.84. Provexis' value of 115.58 is 27.2% above this industry median. Based on the distribution chart, Provexis ranks #145 out of 920 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Provexis' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Provexis ranks #145 out of 920 companies for Days Payable. This places Provexis in the top 16% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.84. Provexis' value of 115.58 is 27.2% above this benchmark. Historically, Provexis' own Days Payable has ranged from 11.78 to 1,788.50 over the past decade. While the company's 10-year median is 182.50 vs. the industry median of 90.84, Provexis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Provexis's current Days Payable of 115.58 is 27.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Provexis and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Provexis's current Days Payable is 115.58, which is 37% below median its own 10-year median of 182.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Provexis stock overvalued right now?
Provexis (CHIX:PXSL) has a current Days Payable of 115.58. The current Days Payable is 115.58, which is 37% below median its 10-year median of 182.50 and 27.2% above the Drug Manufacturers industry median of 90.84. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Provexis (CHIX:PXSL), the current Days Payable is 115.58 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Provexis PLC is engaged in developing, licensing and selling the proprietary, scientific Fruitflow heart-health functional food ingredient for the global functional food sector. The extract is available in two formats, a syrup and a powder, and it can be included in a broad range of food, beverage and dietary supplement formats.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:PXSL has been successfully added to your 